511 related articles for article (PubMed ID: 19933912)
21. Everolimus for advanced pancreatic neuroendocrine tumors.
Yao JC; Shah MH; Ito T; Bohas CL; Wolin EM; Van Cutsem E; Hobday TJ; Okusaka T; Capdevila J; de Vries EG; Tomassetti P; Pavel ME; Hoosen S; Haas T; Lincy J; Lebwohl D; Öberg K;
N Engl J Med; 2011 Feb; 364(6):514-23. PubMed ID: 21306238
[TBL] [Abstract][Full Text] [Related]
22. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.
Chan JA; Blaszkowsky L; Stuart K; Zhu AX; Allen J; Wadlow R; Ryan DP; Meyerhardt J; Gonzalez M; Regan E; Zheng H; Kulke MH
Cancer; 2013 Sep; 119(17):3212-8. PubMed ID: 23733618
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors.
Chan JA; Ryan DP; Zhu AX; Abrams TA; Wolpin BM; Malinowski P; Regan EM; Fuchs CS; Kulke MH
Endocr Relat Cancer; 2012 Oct; 19(5):615-23. PubMed ID: 22736724
[TBL] [Abstract][Full Text] [Related]
24. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
25. Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.
Hobday TJ; Qin R; Reidy-Lagunes D; Moore MJ; Strosberg J; Kaubisch A; Shah M; Kindler HL; Lenz HJ; Chen H; Erlichman C
J Clin Oncol; 2015 May; 33(14):1551-6. PubMed ID: 25488966
[TBL] [Abstract][Full Text] [Related]
26. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
27. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of first-line long-acting octreotide treatment in non-functional, advanced gastroenteropancreatic neuroendocrine tumors.
Saglam S; Hacisahinogullari H; Ozturk N; Kapran Y; Gulluoglu M; Turkmen C; Adalet I; Orhan Bilge A; Cem Balci N
J BUON; 2015; 20(5):1201-5. PubMed ID: 26537065
[TBL] [Abstract][Full Text] [Related]
29. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
Lombard-Bohas C; Yao JC; Hobday T; Van Cutsem E; Wolin EM; Panneerselvam A; Stergiopoulos S; Shah MH; Capdevila J; Pommier R
Pancreas; 2015 Mar; 44(2):181-9. PubMed ID: 25479584
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
31. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F
Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834
[TBL] [Abstract][Full Text] [Related]
32. Everolimus Related Fulminant Hepatitis in Pancreatic Neuroendocrine Tumor With Liver Metastases: A Case Report and Literature Review.
Chang SC; Tsai CY; Liu KH; Wang SY; Hsu JT; Yeh TS; Yeh CN
Front Endocrinol (Lausanne); 2021; 12():639967. PubMed ID: 33868173
[TBL] [Abstract][Full Text] [Related]
33. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study.
Berruti A; Fazio N; Ferrero A; Brizzi MP; Volante M; Nobili E; Tozzi L; Bodei L; Torta M; D'Avolio A; Priola AM; Birocco N; Amoroso V; Biasco G; Papotti M; Dogliotti L
BMC Cancer; 2014 Mar; 14():184. PubMed ID: 24628963
[TBL] [Abstract][Full Text] [Related]
34. Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey.
Falconi M; Fazio N; Ferone D; Versari A
Expert Opin Pharmacother; 2020 Dec; 21(18):2317-2324. PubMed ID: 32990061
[TBL] [Abstract][Full Text] [Related]
35. Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors.
Wolin EM
Chemotherapy; 2014; 60(3):143-50. PubMed ID: 25766415
[TBL] [Abstract][Full Text] [Related]
36. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
[TBL] [Abstract][Full Text] [Related]
37. Update on novel therapies for pancreatic neuroendocrine tumors: 2013.
Dimou A; Syrigos KN; Saif MW
JOP; 2013 Jul; 14(4):377-80. PubMed ID: 23846931
[TBL] [Abstract][Full Text] [Related]
38.
Satapathy S; Mittal BR; Sood A; Sood A; Kapoor R; Gupta R; Khosla D
JCO Glob Oncol; 2021 Jul; 7():1167-1175. PubMed ID: 34288699
[TBL] [Abstract][Full Text] [Related]
39. A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients.
Yao J; Wang JY; Liu Y; Wang B; Li YX; Zhang R; Wang LS; Liu L
Med Oncol; 2014 Dec; 31(12):251. PubMed ID: 25395378
[TBL] [Abstract][Full Text] [Related]
40. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.
Yao JC; Pavel M; Lombard-Bohas C; Van Cutsem E; Voi M; Brandt U; He W; Chen D; Capdevila J; de Vries EGE; Tomassetti P; Hobday T; Pommier R; Öberg K
J Clin Oncol; 2016 Nov; 34(32):3906-3913. PubMed ID: 27621394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
